Webcast: Update on China NMPA & US FDA Emergency Approval - Implications to Life Science Companies Relating to COVID-19

RAC Credits
Live WebcastsLive Webcasts Virtual ProgramsVirtual Programs
Wednesday, 29 April 2020 (11:00 AM) - Wednesday, 29 April 2020 (12:30 PM) Eastern Time (US & Canada)

As COVID-19 has become a pandemic, the time is critical for the support and reassurance that science can offer.

In response to the outbreak, Chinese regulatory authorities adopted emergency measures to fast-track the review and approval process.

China NMPA (former CFDA) issued an unprecedented number of Emergency Approvals of medical devices, diagnostic assays, protective supplies, and sterilization tools. The first batch of diagnostic tests were approved within five days. Furthermore, multiple drugs and biologics are in a clinical trial and various stages of approval. One such example, Remdesivir — an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of the influenza virus — is a potential agent against COVID-19 and was approved within three days to enter a clinical trial.

During this 90 minute webcast, our experts will explain related regulatory, clinical study conduct as well as quality assurance guidelines, emergency approval procedures, urgent importations, how they work in practice, what is required during the COVID-19 crisis, and what to expect moving forward. You will gain an understanding of how these changes will impact market entry to both the US and China.

The topics will cover both China's NMPA and US FDA regulatory updates. We will also discuss China's evolving market dynamics that may impact manufacturers of medical devices, IVD, drugs, and biologics.

Learning Level: Intermediate

Content is designed based upon the assumption that individuals have basic knowledge of the topic(s) and/or demonstrated competence related to the topic(s). Higher-level concepts are introduced during lectures; exercises requiring synthesis and/or application of concepts are incorporated into the activity.

Learning Objectives

Upon conclusion of this webcast, you will:

  • Learn about the products that have received NMPA latest emergency approval due to COVID-19
  • Familiarize yourself with regulatory, clinical and quality assurance relevant regulations and conducts in both China NMPA and FDA
  • Discover the urgently needed products in AI, diagnostics, ICU care, imaging, and more
  • Understand the key implications to your market entry strategy

Who should attend?

  • Managers in the life sciences industry
  • Regulatory affairs professionals
  • Quality affairs professionals
  • Clinical affairs professionals
  • Medical affairs professionals
  • R&D managers
  • Compliance managers
  • Operations managers
  • Marketing and business executives


Grace Fu Palma, MBA, CEO, China Med Device, LLC

Dave McGurl, Director of Regulatory Affairs, MCRA

Yan Sheng, PhD, Project Manager, China Med Device, LLC

Yan Sheng, PhD, is the project manager of China Med Device. She grew up in China working in the life science industry in both the US and China. Sheng received her PhD at Oregon State University. Her PhD studies focused on natural products discovery from the microbial world. With more than 6 years’ experience in the academic field, she is familiar with cutting edge technologies in both chemistry and microbiology.

Linyan Gao, PhD, Partner, China Med Device, LLC

Linyan Gao has 15 years of experience working with China’s regulatory affairs for chemical drugs and biologics. This includes 6 years of experience in the synthesis and quality control of APIs and drug products. Gao’s expertise includes reviewing documents of chemical drugs, biological products and imported drugs, as well as technical and formal review points. Proficient in communication with CDE-NMPA and successful drug application experience. PhD at Peking Union Medical College on microbiology and biochemical pharmacy.

Discover more of what matters to you

News »